MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on December 30, 2004; DOI: 10.1124/mol.104.008417


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.104.008417v1
mol.104.008417v2
67/4/992    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pediani, J. D.
Right arrow Articles by McGrath, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pediani, J. D.
Right arrow Articles by McGrath, J. C.


Received for publication October 19, 2004.
Revised December 21, 2004.
Accepted for publication December 21, 2004.

{beta}-arrestin Dependent Spontaneous {alpha}1a-Adrenoceptor Endocytosis causes Intracellular Transportation of {alpha}-blockers via Recycling Compartments

John Daniel Pediani 1*, Janet Fraser Colston 1, Darren Caldwell 1, Graeme Milligan 2, Craig James Daly 1, John Christie McGrath 1

1 Div of Neuroscience and Biomedical Systems, IBLS, University of Glasgow 2 Div of Biochemistry and Molecular Biology, IBLS, University of Glasgow

* Address correspondence to: E-mail: john.pediani{at}bio.gla.ac.uk

Abstract

The antagonist ligand BODIPY-FL-prazosin (QAPB) fluoresces when bound to bovine {alpha}1a-adrenoceptors (ARs). Data indicates that the receptor-ligand complex is spontaneously internalized by {beta}-arrestin-dependent endocytosis. Internalization of the ligand did not occur in {beta}-arrestin-deficient cells, was blocked or reversed by another {alpha}1 ligand, phentolamine, indicating it to reflect binding to the orthosteric recognition site, and was prevented by blocking clathrin-mediated endocytosis. The ligand showed rapid, diffuse, low-intensity, surface binding, superseded by punctate intracellular binding that developed to equilibrium in 50-60 min, and was reversible on ligand removal, indicating a dynamic equilibrium. In cells expressing a human {alpha}1a-AR-EGFP2 fusion protein, BODIPY-R-558/568-prazosin (RQAPB) co-localized with the fusion, indicating that the ligand gained access to all compartments containing the receptor and, conversely, that the receptor has affinity for the ligand at all of these sites. The distribution of QAPB binding sites was similar for receptors with or without EGFP2, validating the fusion protein as an indicator of receptor location. The ligand partially co-localized with {beta}-arrestin in recycling and late endosomes indicating receptor transit without destruction. Organelles containing receptors showed considerable movement consistent with a transportation function. This was absent in {beta}-arrestin-deficient cells indicating that both constitutive receptor internalization and subsequent intracellular transportation are {beta}-arrestin-dependent. Calculations of relative receptor number suggest that at steady state less than 30% of receptors reside on the cell surface and that recyling is extremely rapid. We conclude that {alpha}1a-ARs recycle rapidly by an agonist-independent, constitutive, {beta}-arrestin-dependent process and that this can transport "{alpha}-blockers" into cells carrying these receptors.


Key words: Adrenergic, Receptor synthesis/trafficking, Sequestration/Internalization, GRKs, barrestins, Recycling, Fluorescence techniques





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics